menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'EU' ×
Caroline Freeman
RobinHuff
The European Medicines Agency clarifies key concepts on orphan drug designation and marketing authorization — which may provide greater predictability for drug developers.
Read More
Chris Bamford
How Regulation 536/2014 will impact the way developers conduct research in the EU.
Read More
Jeremy Broadis
Obtaining regional and local market access in the age of health technology assessments.
Read More
DeanSummerfield
Exploring the challenges HTA bodies face keeping pace with fast track approval paths and value as defined by the patient.
Read More
Anke van Engen
How this relatively new US-based HTA framework could change the conversation about value and affordability.
Read More
Anke van Engen
Developers pursing accelerated pathways should work with payers to understand what evidence needs to be obtained to increase the chance of a positive recommendation.
Read More
Robert Taylor
To improve probability of success and to stay relevant in a tough European market, biopharma companies need a new commercial partnering approach.
Read More
Sascha Nussbaum
Caroline Freeman